At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib cream and Vehicle cream for Lichen Sclerosus. Completed, enrolled 61 participants across 14 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants With Lichen Sclerosus. This is randomized, double-blind, vehicle-controlled (DBVC) study with a DBVC period of 12 weeks followed by an open label period (OLE) period of 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLichen Sclerosus
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartNov 2022
Primary CompletionSep 2023
Study CompletionDec 2023
TodayJul 2026
First PostedOct 25, 2022
Enrollment StartNov 18, 2022
Primary CompletionSep 1, 2023
Study CompletionDec 21, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.7 years ago
Interventions
Ruxolitinib creamdrug
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Vehicle creamdrug
Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.